In the News
One-hour glucose tolerance test outperforms two-hour test for predicting progression to diabetes
Machine learning was used to combine different variables, including clinical risk factors, plasma glucose and insulin levels, HbA1c level, and six metabolic markers, in 1,527 models for predicting progression risk.
New equation with five variables helps predict hip fracture risk in type 2 diabetes
Age, sex, body mass index, peripheral sensory neuropathy, and estimated glomerular filtration rate were the included variables.
SGLT2 inhibitors associated with increased risk of amputations, diabetic ketoacidosis
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and acute pancreatitis.
MKSAP question: Chest pressure and dyspnea
This month's quiz asks readers to evaluate a patient with type 2 diabetes who has chest pressure and dyspnea despite maximal medical therapy.
Spotlight on cost-related nonadherence
Recent studies looked at how often patients underuse insulin due to cost, whether Supplemental Nutrition Assistance Program participation reduces cost-related nonadherence, and how high deductibles affect the timing of care for macrovascular complications.
FDA issues draft guidance on blood glucose monitors
The updated recommendations apply to industry and, when finalized, will update previous guidance issued in 2016.
Liraglutide provided cardiovascular benefit to oldest patients, post hoc analysis finds
Researchers analyzed the industry-funded LEADER trial, focusing on the oldest patients who were randomized to liraglutide or placebo.
Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes
Available risk scores are in need of recalibration but still serve as useful decision-making tools, according to an ACP Journal Club commentary.
Expert panel recommends SGLT2 inhibitor or GLP-1 receptor agonist for patients with type 2 diabetes and CVD
The American College of Cardiology's new decision pathway also calls for repeated HbA1c screening and detailed clinician-patient risk discussions for patients with cardiovascular disease (CVD) who are diagnosed with type 2 diabetes.
Diabetes outcomes similar when primary care provided by NPs, PAs, or physicians, study finds
More care by nurse practitioners (NPs) and physician assistants (PAs) may be a way to expand primary care access while maintaining quality standards.